No profile data available.
Silence Therapeutics plc (SLN) is a healthcare company in the multi-therapeutic drug manufacturing industry, based in London, United Kingdom, with about 116 full-time employees.
It reported revenue of $559,000 for fiscal year 2025, down 98.7% from fiscal year 2024, and net income of -$88.61 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0, down 100.0% from a year before. Its market capitalization was $336.78 million as of December 4, 2025.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of December 4, 2025.
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases.
Silence Therapeutics reported $559,000 in revenue for fiscal year 2025, down 98.7% from $43.26 million in fiscal year 2024. In Q2 2026 revenue was $0.
$336.78 million as of December 4, 2025.
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Kamada Ltd. (KMDA), Nika Pharmaceuticals, INC (NIKA), Emergent BioSolutions Inc. (EBS), Contineum Therapeutics, Inc. (CTNM).